Mesenchymal Stem Cells and Cardiovascular Diseases
Article Sidebar
Main Article Content
Abstract
Stem cell therapy has begun as a promising and novel approach for the treatment of various diseases. Stem cell therapy involves the identification of correct cells, area of transplantation. Transplantation of functional and healthy stem cells help to renewal of damaged cells and repair injured tissue. Stem cell isolated from bone marrow were the first cell type used in preclinical and clinical investigations for the have been extended to the use of various populations of stem cells. But there are very few studies which show the roles of stem cells in cardiovascular disease. Cardiovascular Disease (CVD) constitutes the most important cause of mortality and morbidity worldwide. CVD represents a group of disorders connected with the defeat of cardiac function. In spite of significant advances in the understanding of the pathophysiological mechanisms of the disease, the problem of cardiac tissue loss has not yet been addressed. Only few therapeutic approaches suggest through tissue repair and regeneration. The most of treatment options aim to control the scar formation and adverse remodeling, while improving myocardial function. Of all the existing therapeutic approaches, the problem of cardiac tissue loss is addressed uniquely by heart transplantation. This review addresses the present state of research as regards stem cell therapy for CVD.
Downloads
Article Details
Copyright (c) 2020 Mehdi AG, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Jayaraj JC, Davatyan K, Subramanian SS, Priya J (2018) Epidemiology of Myocardial Infarction. Intech Open. Link: https://bit.ly/3bLrcwf
Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, et al. (2012) ESC Guidelines for the management of acute myocardial infarction in patients presenting with S-Tsegment elevation. Eur Heart J 33: 2569-2619. Link: https://bit.ly/3cUyq0U
Coventry LL, Finn J, Bremner AP (2011) Sex difference in symptom presentation in acute myocardial infarction: a systematic review and meta-analysis. Heart Lung 40: 477-491. Link: https://bit.ly/3f01xlc
Valensi P, Lorgis L, Cottin Y (2011) Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: a review of the literature. Arch Cardiovasc Dis 104: 178-188. Link: https://bit.ly/35cWhGL
Eltyeb A, Tomasz S, César GSL, Carvalho KAT, Gallo P, et al. (2011) Stem cell therapy in heart diseases: a review of selected new perspectives, practical considerations and clinical applications. Curr Cardiol Rev 7: 201-212. Link: https://bit.ly/2VG3NGS
Ji ST, Kim H, Yun J, Chung JS, Kwon SM (2017) Promising therapeutic strategies for mesenchymal stem cell-based cardiovascular regeneration: from cell priming to tissue engineering. Stem Cells Int 2017: 3945403: Link: https://bit.ly/3aLcQKK
Xin M, Olson EN, Bassel-Duby R (2013) Mending broken hearts: Cardiac development as a basis for adult heart regeneration and repair. Nat Rev Mol Cell Biol 14: 529-541. Link: https://bit.ly/3aCWJ20
Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnabé-Heider F, et al. (2009) Evidence for cardiomyocyte renewal in humans. Science 324: 98-102. Link: https://bit.ly/35mJTnH
Vizoso FN, Eiro S, Cid JS, Perez-Fernandez R (2017) Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. International Journal of Molecular Sciences 18: 1852. Link: https://bit.ly/3cUQ4l8
Sanina C, Hare JM (2015) Mesenchymal stem cells as a biological drug for heart disease: where are we with cardiac cellbased therapy?. Circ Res 117: 229-233. Link: https://bit.ly/3eX9dom
Sell SP (2004) Stem cell handbook, Humana Press Inc, New Jersey. Link: https://bit.ly/3eWLnZT
Saito K, Kuang J, Lin C, Chiu R (2003) Transcoronary implantation of bone marrow stromal cells ameliorates cardiac function after myocardial infarction. J Thorac Cardio vasc Surg 126: 114-123. Link: https://bit.ly/2SdSF1M
Smith AR, Wagner JE (2009) Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood. Br J Haematol 147: 246-261. Link: https://bit.ly/2VLkoJw
Zhong XY, Zhang B, Asadollahi R, Low SH, Holzgreve W (2010) Umbilical cord blood stem cells: what to expect. Ann N Y Acad Sci 1205: 17-22. Link: https://bit.ly/3bN4IuA
Newman MB, Davis CD, Borlongan CV, Emerich D, Sanberg PR (2004) Transplantation of human umbilical cord blood cells in the repair of CNS diseases. Expert Opin Biol Ther 4: 121-130. Link: https://bit.ly/3bMjYrJ
Bronxmeyer HE, Srour EF, Hangoc G, Cooper S, Anderson SA, et al. (2003) High-efficiency recovery of functional hematopoetic progenitor and stem cells from human cord blood cryopreserved for 15 years. Proc Natl AcadSci U S A 100: 645-650. Link: https://bit.ly/2SdmzmU
Gluckman E, Ruggeri A, Volt F, Cunha R, Boudjedir K, et al. (2011) Milestones in umbilical cord blood transplantation. Br J Haematol 154: 441-447. Link: https://bit.ly/3eVxT0B
Orlic D, Girard LJ, Anderson SM, Do BK, Seidel NE, et al. (1997) Transduction efficiency of cell lines and hematopoietic stem cells correlates with retrovirus receptor mRNA levels. Stem Cells 15: 23-29. Link: https://bit.ly/3bIWpzX
Hows JM, Marsh JC, Bradley BA, Luft T, Coutinho L, et al. (1992) Human cord blood: a source of transplantable stem cells? Bone Marrow Transplant 9: 105-108. Link: https://bit.ly/2KFJ2oq
Ratajczak MZ, Suszynska M, Pedziwiatr D, Mierzejewska K, Greco NJ (2012) Umbilical cord bloodderived very small embryonic like stem cells (VSELs) as a source of pluripotent stem cells for regenerative medicine. Pediatr Endocrinol Rev 9: 639-643. Link: https://bit.ly/2W219dq
Zeng H, Li I, Chen LX (2012) Overexpression of angiopoietin-1 increases CD133+/c-kit+ cells and reduces myocardial apoptosis in db/db mouse infarcted hearts. PLoS One 7: e35905. Link: https://bit.ly/2SdDeqa
Orlic D, Kajstura J, Chimenti S, Jakoniuk I, Anderson SM, et al. (2001) Bone marrow cells regenerate infarcted myocardium. Nature 410: 701-705. Link: https://bit.ly/2KEuQMz
Fang CH, Jin J, Joe JH, Song YS, So BI, et al. (2012) In Vivo Differentiation of Human Amniotic Epithelial Cells into Cardiomyocyte-Like Cells and Cell Transplantation Effect on Myocardial Infarction in Rats: Comparison with Cord Blood and Adipose Tissue-Derived Mesenchymal Stem Cells. Cell Transplant 21: 1687-1696. Link: https://bit.ly/2W4ANYj
MacDonald DJ, Luo J, Saito T, Duong M, Bernier PL, et al. (2005) Persistence of marrow stromal cells implanted into acutely infarcted myocardium: observations in a xenotransplant model. J Thorac Cardiovasc Surg 130: 1114-1121. Link: https://bit.ly/3cRzYJ9
Amado LC, Saliaris AP, Schuleri KH, St John M, Xie JS, et al. (2005) Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction. Proc Natl Acad Sci U S A 102: 11474-11479. Link: https://bit.ly/2W3XxaR
Gaebel R, Furlani D, Sorg H, Polchow B, Frank J, et al. (2011) Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration. PLoS One 6: e15652. Link: https://bit.ly/2xUlLMR
Hassan F, Meduru S, Taguchi K, Kuppusamy K, Mostafa M, et al. (2012) Carvedilol enhances mesenchymal stem cell therapy for myocardial infarction via inhibition of caspase-3 expression. J Pharmacol ExpTher 343: 62-71. Link: https://bit.ly/2VJnu0s
Cerrada I, Ruiz-Sarui A, Carrerro R, Trigueros C, Dorronsoro A, et al. (2012) Hypoxia-inducible factor 1 alpha contributes to cardiac healing in mesenchymalstem cells mediated cardiac repair. Stem Cells Dev 22: 501-511. Link: https://bit.ly/3bLi36O
Wang JS, Kovanecz I, Vernet D, Nolazco G, Kopchok GE, et al. (2012) Effects of sildenafil and/or muscle derived stem cells on myocardial infarction. J Transl Med 10: 159. Link: https://bit.ly/2VJIG6I
Dib N, Michler RE, Pagani FD, Wright S, Kereiakes DJ, et al. (2005) Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up. Circulation 112: 748-1755. Link: https://bit.ly/3bLfotI
Povsic TJ, O’Connor CM, Henry T, Taussig A, Kereiakes DJ, et al. (2011) A double-blind, randomized, controlled, multicenter study to assess the safety and cardiovascular effects of skeletal myoblast implantation by catheter delivery in patients with chronic heart failure after myocardial infarction. Am Heart J 162: 654-662. Link: https://bit.ly/2VIq1rF
Konoplyannikov M, Haider K, Lai VK, Ahmed RP, Jinag S, et al. (2012) Activation of diverse signaling pathways by ex-vivo delivery of multiple cytokines for myocardial repair. Stem Cells Dev 22: 204-215. Link: https://bit.ly/2VH3g7B
Von WR, Blumenthal B, Heilmann C, Golsong P, Poppe A, et al. (2012) Scaffold-based transplantation of vascular endothelial growth factor-overexpressing stem cells leads to neovascularization in ischemic myocardium but did not show a functional regenerative effect. ASAIO J 58: 268-274. Link: https://bit.ly/3aKYvyb
Mozid AM, Arnous S, Sammut EC, Mathur A (2011) Stem cell therapy for heart diseases. Br Med Bull 98: 143-159. Link:
Lee S, Choi E, Cha MJ, Hwang KC (2015) Cell adhesion and long-term survival of transplanted mesenchymal stem cells: a prerequisite for cell therapy. Oxid Med Cell Longev 2015: 632902. Link: https://bit.ly/2W5yBQf
Miao C, Lei M, Hu W, Han S, Wang Q (2017) A brief review: the therapeutic potential of bone marrow mesenchymal stem cells in myocardial infarction. Stem Cell Res Ther 8: 242. Link: https://bit.ly/2Ye2Irh
Huang P, Wang LI, Li Q, Xu J, Xu J, et al. (2019) Combinatorial treatment of acute myocardial infarction using stem cells and their derived exosomes resulted in improved heart performance. Stem Cell Res Ther 10: 300. Link: https://bit.ly/2xUnjXb
Liu B, Duan CY, Luo CF, Ou CW, Sun K, et al. (2014) Effectiveness and safety of selected bone marrow stem cells on left ventricular function in patients with acute myocardial infarction: a meta-analysis of randomized controlled trials. Int J Cardiol 177: 764-770. Link: https://bit.ly/2SeX1Wk
Maguire G (2014) Stem cell therapy without the cells. Commun Integr Biol 6: e26631. Link:
Wu Y, Zhao RC (2012) The role of chemokines in mesenchymal stem cell homing to myocardium. Stem Cell Rev Rep 8: 243-250. Link: https://bit.ly/2KGF7Yo
Tong J, Ding J, Shen X, Chen L, Bian Y, et al. (2013) Mesenchymal stem cell transplantation enhancement in myocardial infarction rat model under ultrasound combined with nitric oxide microbubbles. PLoS One 8: e80186. Link: https://bit.ly/2KFRPXn
Won YW, Patel AN, Bull DA (2014) Cell surface engineering to enhance mesenchymal stem cell migration toward an SDF-1 gradient. Biomaterials 35: 5627-5635. Link: https://bit.ly/2y8MpkW
Williams AR, Hatzistergos KE, Addicott B, McCall F, Carvalho D, et al. (2013) Enhanced effect of combining human cardiac stem cells and bone marrow mesenchymal stem cells to reduce infarct size and to restore cardiac function after myocardial infarction. Circulation 127: 213-223. Link: https://bit.ly/2KHGJ46
Mao Q, Lin C, Gao J, Liang X, Gao W, et al. (2014) Mesenchymal stem cells overexpressing integrinlinked kinase attenuate left ventricular remodeling and improve cardiac function after myocardial infarction. Mol Cell Biochem 397: 203-214. Link: https://bit.ly/3cUUjNA
Sheu JJ, Lee FY, Yuen CM, Chen YL, Huang TH, et al. (2015) Combined therapy with shock wave and autologous bone marrow-derived mesenchymal stem cells alleviates left ventricular dysfunction and remodeling through inhibiting inflammatory stimuli, oxidative stress & enhancing angiogenesis in a swine myocardial infarction model. Int J Cardiol 193: 69-83. Link: https://bit.ly/3aGUV7Z
Miyahara Y, Nagaya N, Kataoka M, Yanagwa B, Tanaka K, et al. (2006) Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med 459-465. Link: https://bit.ly/2yKLYNP
Rangappa S, Entwistle JW, Wechsler AS, Kresh JY (2003) Cardiomyocyte-mediated contact programs human mesenchymal stem cells to express cardiogenic phenotype. J Thorac Cardiovasc Surg 126: 124-132. Link: https://bit.ly/3cRuMVC
Li X, Yu X, Lin Q, Deng C, Shan Z, et al. (2007) Bone marrow mesenchymal stem cells differentiate into functional cardiac phenotypes by cardiac microenvironment. J Mol Cell Cardiol 42: 295-303. Link: https://bit.ly/3bKntyJ
Schutt RC, Trachtenberg BH, Cooke JP, Traverse JH, Henry TD, et al. (2015) Bone marrow characteristics associated wi-th changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial. Circ Res 116: 99-107. Link: https://bit.ly/2VG8NeC
Gao LR, Chen Y, Zhang NK, Yang XL, Liu H, et al. (2015) Intracoronary infusion of Wharton’s jelly-derived mesenchymal stem cells in acute myocardial infarction: double-blind, randomized controlled trial. BMC Med 13: 162. Link: https://bit.ly/3cV6ni8
Florea V, Rieger AC, DiFede DL, El-Khorazaty J, Natsumeda M, et al. (2017) Dose comparison study of allogeneic mesenchymal stem cells in patients with ischemic cardiomyopathy (The TRIDENT study). Circ Res 121: 1279-1290. Link: https://bit.ly/3eQIz0q
Chullikana A, Majumdar AS, Gottipamula S, Krishnamurthy S, Kumar AS, et al. (2015) Randomized, double-blind , phase I/II study of intravenous allogeneic mesenchymal stromal cells in acute myocardial infarction. Cytotherapy 17: 250-261. Link: https://bit.ly/3cXmLia
Can A, Ulus AT, Cinar O, Topal Celikkan F, Simsek E, et al. (2015) Human umbilical cord mesenchymal stromal cell transplantation in myocardial ischemia (HUC-HEART Trial). A study protocol of a phase 1/2, controlled and randomized trial in combination with coronary artery bypass grafting. Stem Cell Rev Rep 11: 752-760. Link: https://bit.ly/2W6EooG